Elevated serum lipoprotein(a) is a risk factor for left atrial thrombus in patients with chronic atrial fibrillation: A transesophageal echocardiographic study

1998 ◽  
Vol 136 (6) ◽  
pp. 965-971 ◽  
Author(s):  
Yutaka Igarashi ◽  
Masayuki Yamaura ◽  
Masahiro Ito ◽  
Hiroshi Inuzuka ◽  
Kenji Ojima ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Risk Factor ◽  
Left Atrial ◽  
Elevated Serum ◽  
Chronic Atrial Fibrillation ◽  
Serum Lipoprotein ◽  
Left Atrial Thrombus ◽  
Atrial Thrombus ◽  
Lipoprotein A ◽  
Echocardiographic Study

scholarly journals Thrombus Formation in Left Atrium on Dabigatran Therapy

2015 ◽  
Vol 2015 ◽  
pp. 1-2 ◽  
Author(s):  
Priyank Shah ◽  
Priyam Mithawala ◽  
Donna Konlian ◽  
Aderemi Soyombo ◽  
Mahesh Bikkina
Keyword(s):  
Atrial Fibrillation ◽  
Left Atrium ◽  
Left Atrial ◽  
Thrombus Formation ◽  
Chronic Atrial Fibrillation ◽  
The United States ◽  
Thrombin Inhibitor ◽  
Left Atrial Thrombus ◽  
Nonvalvular Atrial Fibrillation ◽  
Atrial Thrombus

Dabigatran is a direct thrombin inhibitor, approved in the United States for stroke prevention in nonvalvular atrial fibrillation and prevention and treatment of thromboembolism. It has been also used in patients with documented left atrial thrombus, where treatment with dabigatran effectively led to thrombus resolution. We present a rare case of left atrial thrombus formation in a patient with chronic atrial fibrillation being treated with dabigatran 150 mg twice a day. The patient presented with multiple embolic strokes. There are only three such cases reported in the literature till date, all of whom had thrombus in the left atrium. The possible mechanisms of dabigatran failure include compensatory increase in upstream coagulation factors due to single level downstream blockade of thrombin, lack of inhibition of all available thrombin, and lack of monitoring measures that can be implemented in common clinical laboratories that lead to failure to assess adherence, which in turn can lead to dabigatran failure.

Age alone is not a risk factor for left atrial thrombus in atrial fibrillation

Heart ◽  
2008 ◽  
Vol 94 (2) ◽  
pp. 197-199 ◽  
Author(s):  
B Mazouz ◽  
A Keren ◽  
A Chenzbraun
Keyword(s):  
Atrial Fibrillation ◽  
Risk Factor ◽  
Left Atrial ◽  
Left Atrial Thrombus ◽  
Atrial Thrombus

Elevated Serum Lipoprotein(a) Is a Risk Factor for Clinical Recurrence After Coronary Balloon Angioplasty

Circulation ◽  
1995 ◽  
Vol 91 (5) ◽  
pp. 1403-1409 ◽  
Author(s):  
Rene L. Desmarais ◽  
Ian J. Sarembock ◽  
Carlos R. Ayers ◽  
Sarah M. Vernon ◽  
Eric R. Powers ◽  
...  
Keyword(s):  
Risk Factor ◽  
Balloon Angioplasty ◽  
Elevated Serum ◽  
Serum Lipoprotein ◽  
Clinical Recurrence ◽  
Lipoprotein A

scholarly journals NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world

2017 ◽  
Vol 249 ◽  
pp. 179-183 ◽  
Author(s):  
Emanuele Bertaglia ◽  
Matteo Anselmino ◽  
Alessandro Zorzi ◽  
Vincenzo Russo ◽  
Elisabetta Toso ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Real World ◽  
Left Atrial ◽  
Left Atrial Thrombus ◽  
Atrial Thrombus ◽  
The Real
Sign in / Sign up

Export Citation Format

Share Document